Quick answers

What is CJC-1295 and what is it used for in research?
CJC-1295 is classified within the GH Secretagogue group. Modified GHRH(1-29) without DAC, short half-life. Daily SC dosing. The DAC variant is a separate SKU. Research applications focus on the pathways outlined below. All references on this page describe published research only, CJC-1295 is supplied for in-vitro and laboratory use, not for human consumption.
How does CJC-1295 work?
Primary mechanism: GHRH analog (No DAC, daily dosing). Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for CJC-1295 remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical CJC-1295 research dose?
Published research protocols for CJC-1295 describe per-dose ranges of 100 mcg × 2–3 / day, with a weekly total near 1.4–2.1 mg, administered daily sc. Typical cycle: 12 weeks on / 4 off. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy CJC-1295 in Thailand?
CJC-1295 is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk, no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can CJC-1295 be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

What is CJC-1295?

CJC-1295 is a research peptide in the GH Secretagogue class. GHRH analog (No DAC, daily dosing). It is studied at per-dose ranges of 100 mcg × 2–3 / day (1.4–2.1 mg weekly), administered daily sc over cycles of 12 weeks on / 4 off. Supplied in Thailand by Thailand Peptides, Bangkok-based, research use only.

Modified GHRH(1-29) without DAC, short half-life. Daily SC dosing. The DAC variant is a separate SKU.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does CJC-1295 work?

CJC-1295 is a modified GHRH(1-29) analogue. The DAC (Drug Affinity Complex) variant carries a maleimidopropionic acid linker that forms a covalent bond with circulating albumin, dramatically extending half-life and producing sustained elevation of baseline GH and IGF-1. Like native GHRH, it acts on the GHRH receptor on somatotrophs, but its pharmacology is closer to continuous stimulation than pulsatile release.

Receptor binding affinity and post-receptor signalling for CJC-1295 remain areas of active investigation; several proposed effects within the GH Secretagogue class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

CJC-1295 pharmacokinetics

Half-life
DAC-modified variant: approximately 8 days due to covalent albumin binding. Non-DAC (mod-GRF 1-29): ~30 minutes.
Bioavailability
SC bioavailability described as high in Phase 1 trials of the DAC variant.
Route of administration
Subcutaneous injection 1–2× weekly for the DAC form; the non-DAC form is dosed multiple times daily.
Metabolic clearance
Proteolytic degradation while bound to albumin; cleared gradually as albumin turns over.

CJC-1295 research timeline

  1. 2006 Teichman et al., prolonged GH and IGF-1 elevation with weekly SC CJC-1295 (J Clin Endocrinol Metab).

CJC-1295 dosage & protocol

Reference protocol for CJC-1295 (research context only, drawn from published literature):

  • Per dose: 100 mcg × 2–3 / day
  • Weekly total: 1.4–2.1 mg
  • Frequency: Daily SC
  • Cycle: 12 weeks on / 4 off

CJC-1295 injection & handling

Reconstitution
Typical research prep: 2 mg vial + 2 mL bacteriostatic water, yielding 1 mg/mL.
Storage
Lyophilised powder at −20 °C; reconstituted solution refrigerated and stable for 2–4 weeks in research protocols.
Sites used in the research literature
Subcutaneous abdomen; weekly dosing simplifies site rotation.

Handling notes reflect methods used in published research protocols, not medical dosing guidance.

Order CJC-1295
Ready to order? WhatsApp the Bangkok research desk, pricing and availability confirmed within the chat.
Ask about CJC-1295 ≥98% HPLC purity · supplier COA on file · Bangkok-based

Stacking CJC-1295

Commonly referenced pairing with CJC-1295: Ipamorelin. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a CJC-1295 stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Active malignancy, pregnancy. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

Further reading

Citations

  1. Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006. PMID: 16352683
  2. Ionescu M, et al. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006. PMID: 17018654

References curated from PubMed. Additional literature summarised in the Thailand Peptides research library.